News Headlines Article

FDA panel recommends rescinding Avastin for breast cancer
San Francisco Business Times

A federal advisory panel is recommending that the Food and Drug Administration remove Genentech Inc.’s multibillion-dollar cancer drug Avastin as an approved treatment for a type of breast cancer. The recommendation from the panel of experts — if the FDA follows suit — could disgorge about $1 billion in breast cancer sales from Avastin, which records sales in excess of $6 billion a year. The FDA is expected to make its final decision by Sept. 17. Avastin costs about $40,000 for a course of treatment.